<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03313076</url>
  </required_header>
  <id_info>
    <org_study_id>17-1971</org_study_id>
    <nct_id>NCT03313076</nct_id>
  </id_info>
  <brief_title>Vitamin D and n-3 Polyunsaturated Fatty Acids (PUFAs) to Prevent Chronic Pain Following Major Thermal Burn Injury</brief_title>
  <official_title>Pilot, Double-blind, Randomized Controlled, Multi-center Study of the Effects of Fish Oil and Vitamin D in the Prevention of Chronic Pain Following Major Thermal Burn Injury</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of North Carolina, Chapel Hill</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of North Carolina, Chapel Hill</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this study is to develop a safe, effective, and readily available treatment that&#xD;
      will prevent chronic pain following Major Thermal Burn Injury (MThBI). Burn survivors are&#xD;
      prone to develop chronic pain and there is an urgent unmet need for preventative treatments.&#xD;
      The preventative treatments proposed for this study, Omega-3 Fatty Acids (O3FA) and Vitamin D&#xD;
      have been selected given effectiveness across a range of painful musculoskeletal disorders&#xD;
      and their wide availability and low cost. This study is a 2x2 factorial, double-blind,&#xD;
      placebo-controlled randomized controlled trial test for the effectiveness of O3FA and Vitamin&#xD;
      D to prevent chronic pain development. Burn survivors will be enrolled who have experienced&#xD;
      thermal burns that cover less than 30% total body surface area that are severe enough to&#xD;
      warrant surgical management, which represents the most common burn injury characteristics.&#xD;
      Patients will be enrolled within 72 hours of their burn, and randomized via 1:1:1:1&#xD;
      allocation to receive placebo, O3FA, Vitamin D or both. The investigators will obtain blood&#xD;
      samples on enrollment and at 6 weeks to assist in elucidating key mechanisms by which O3FA&#xD;
      and Vitamin D reduce chronic pain following MThBI. Chronic pain severity, assessed with a&#xD;
      0-10 numeric rating scale at 6 weeks, 3 months, 6 months and 1 year will be entered into a&#xD;
      repeated-measures model. Model estimated contrasts will serve as the primary outcome.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be screened daily. Patients who meet eligibility criteria will be approached&#xD;
      for participation. Patients interested in participating will proceed through informed&#xD;
      consent. Once informed consent is obtained, an initial questionnaire will be administered, a&#xD;
      blood draw will be performed to assess for baseline Vitamin D/O3FA concentration and immune&#xD;
      profile. Then patients will be randomized into one of 4 treatment arms in 1:1:1:1 allocation.&#xD;
      Patients will receive study drug for 6 weeks following burn injury. Adverse event monitoring&#xD;
      will occur daily while inpatient and weekly once discharged from the hospital through 6&#xD;
      weeks. Patient compliance with the study drug will be assessed via patient-reported reported&#xD;
      missing doses, pill counts at the end of the study, and a 6-week blood draw in which Vitamin&#xD;
      D/O3FA levels and immune profile will be assessed. Patient-reported outcomes will be&#xD;
      collected via follow-up survey at 6 weeks, 3 months, 6 months, and 1 year following burn&#xD;
      injury.s, and 1 year following burn injury.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    COVID-19 global pandemic, and study funding period ended 7/31/2020.&#xD;
  </why_stopped>
  <start_date type="Actual">July 19, 2018</start_date>
  <completion_date type="Actual">July 31, 2020</completion_date>
  <primary_completion_date type="Actual">July 31, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <intervention_model_description>2x2 Factorial design</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double-blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Qualitative Review of Treatment-Related Adverse Events</measure>
    <time_frame>6 weeks following burn injury</time_frame>
    <description>A primary objective of this pilot study is to ensure safety of both treatments as well as combined. A qualitative review of treatment-related adverse events will be performed and a determination about the degree of relatedness of each adverse event with the intervention using CTCAE criteria will be made as CTCAE criteria assesses relatedness to therapy. Investigator reviewing the details of each adverse event rated the likelihood of relatedness to the study drug on a scale: (unrelated, unlikely, possible, probably, definitely).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent of Participants Who Are Compliant With Follow-up (Feasibility)</measure>
    <time_frame>6 weeks following burn injury</time_frame>
    <description>The primary objective of this pilot study is to ensure that the investigators are able to make follow-up assessments on a majority of participants. The percent of participants who are compliant with follow-up will be determined 6 weeks following major thermal burn injury. Feasibility is defined as &gt;80% of enrolled participants at 6 weeks following Major Thermal Burn Injury (MThBI).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>By Group Efficacy Estimates Over Year Following Thermal Burn Injury</measure>
    <time_frame>Over 1 year following MThBI</time_frame>
    <description>Estimates of efficacy will be obtained via repeated measures analysis of pain severity over the 1 year following injury using mixed effects models. Pain will be assessed using a 0-10 numeric rating scale with 0 indicating no pain and 10 indicating pain as severe as you can imagine. Higher scores represent worse outcome. These values (collected in identical fashion over 1 year following burn injury) will be entered into a linear mixed model, and overall effect estimates (beta coefficients) among groups will be determined. Final model was a piece-wise linear mixed model, with a cut-point at 6 weeks. Mixed models were adjusted for age, sex, race, initial pain severity. Every 1 unit change in beta coefficient represents a 1 unit change in pain severity on the 0-10 numeric rating scale.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sex Differences in Treatment Response Based on Pain Scores</measure>
    <time_frame>6 weeks following burn injury</time_frame>
    <description>Examines existence of gender-based treatment response differences in pain severity measured by a 0-10 numeric rating scale where 0 is no pain and 10 is the most severe pain. Higher scores reflect greater pain (poor outcome).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>General Mental Health as Measured by the Short Form (SF)-12 General Mental Health Component Scores</measure>
    <time_frame>6 weeks following burn injury</time_frame>
    <description>Assessment of mental health will be determined by the short form (SF)-12 mental component score. The short form SF-12 Health Survey is a 12-item participant completed questionnaire to measure general health. It includes a mental component score (MCS): ranging from 0 to 100 points. Low values represent a poor health state and high values represent a good mental health.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>General Physical Health by Treatment Group Measured by the SF-12 General Physical Health Component Scores</measure>
    <time_frame>6 weeks following burn injury</time_frame>
    <description>Assessment of physical health will be determined by the SF-12 physical component score. The SF-12 Health Survey is a 12 item participant completed questionnaire to measure general health. It includes a physical component score (PCS): ranging from 0 to 100 points. Low values represent a poor physical health and high values represent a good physical health.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain Interference by Treatment Group Measured by the Brief Pain Inventory</measure>
    <time_frame>6 weeks following burn injury</time_frame>
    <description>The degree to which pain interferes with important life function will be determined by the Brief Pain Inventory. This is a validated, self-reported scale that measures the severity of pain based on the average pain experienced and assesses impact of pain across 7 domains of life function (e.g., enjoyment of life, relationships, normal work). The total severity scores range from 0 (no interference) to 70 (maximum interference). Higher scores reflect greater pain interference.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Chronic Pain Following Thermal Burn Injury</condition>
  <arm_group>
    <arm_group_label>n-3 PUFA (O3FA) + Vitamin D3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4g fish oil in 4 softgels (n-3 PUFA/O3FA) + 2000 IU Vitamin D3 in 1 capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>n-3 PUFA (O3FA) Placebo + Vitamin D3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4g of corn/soy oil blend in 4 softgels + 2000 IU Vitamin D3 in 1 capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>n-3 PUFAs (O3FA) + Vitamin D3 Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4g fish oil in 4 softgels (n-3 PUFA/O3FA) + Vitamin D3 matching Placebo, an inert white powder placebo in 1 capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>n-3 PUFA (O3FA) Placebo + Vitamin D3 Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>4g n-3 PUFA/O3FA Matching Placebo, a corn/soy oil blend in 4 softgels + inert white powder Vitamin D3 matching placebo in 1 capsule</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omega-3 fatty acids (fish oil)</intervention_name>
    <description>4 capsules comprising approximately 2 grams of Eicosapentaenoic acid/Docosahexaenoic acid (EPA/DHA) in a 3:2 ratio (this will require a total dose of 4 grams of fish oil). This will be administered daily, by mouth for 6 weeks</description>
    <arm_group_label>n-3 PUFA (O3FA) + Vitamin D3</arm_group_label>
    <arm_group_label>n-3 PUFAs (O3FA) + Vitamin D3 Placebo</arm_group_label>
    <other_name>Fish oil</other_name>
    <other_name>n-3 fatty acids</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin D3 (cholecalciferol)</intervention_name>
    <description>1 capsule containing 2000 IU of Vitamin D3. This will be administered daily, by mouth for 6 weeks following enrollment.</description>
    <arm_group_label>n-3 PUFA (O3FA) + Vitamin D3</arm_group_label>
    <arm_group_label>n-3 PUFA (O3FA) Placebo + Vitamin D3</arm_group_label>
    <other_name>Cholecalciferol</other_name>
    <other_name>Vitamin D3</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin D3 (cholecalciferol) placebo</intervention_name>
    <description>1 capsule containing inert substance. This will be administered daily, by mouth for 6 weeks following enrollment.</description>
    <arm_group_label>n-3 PUFA (O3FA) Placebo + Vitamin D3 Placebo</arm_group_label>
    <arm_group_label>n-3 PUFAs (O3FA) + Vitamin D3 Placebo</arm_group_label>
    <other_name>Placebo, inert white powder</other_name>
    <other_name>Vitamin D3 Matching Placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omega-3 fatty acid placebo</intervention_name>
    <description>4g of corn/soy oil blend in 4 softgels. This will be administered daily, by mouth for 6 weeks following enrollment.</description>
    <arm_group_label>n-3 PUFA (O3FA) Placebo + Vitamin D3</arm_group_label>
    <arm_group_label>n-3 PUFA (O3FA) Placebo + Vitamin D3 Placebo</arm_group_label>
    <other_name>Placebo, corn/soy oil soft gels</other_name>
    <other_name>PUFA Matching Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ≥ 18 years and ≤ 65 years of age&#xD;
&#xD;
          -  Admitted to burn center within 72 hours of thermal burn injury&#xD;
&#xD;
          -  Estimated Total Body Surface area (TBSA) ≤ 30%&#xD;
&#xD;
          -  Surgical team has plans for surgical management of the burn wound (e.g. xenograft&#xD;
             and/or autograft).&#xD;
&#xD;
          -  Patients experience a thermal burn injury, not an electrical or chemical burn.&#xD;
&#xD;
          -  Has a telephone to receive follow-up calls.&#xD;
&#xD;
          -  Able to speak and read English&#xD;
&#xD;
          -  Resides within 150 miles of study site&#xD;
&#xD;
          -  Alert and oriented&#xD;
&#xD;
          -  Willing to take study medication for 6 weeks following enrollment&#xD;
&#xD;
          -  Subjects are capable of giving informed consent.&#xD;
&#xD;
          -  Predicted probability of chronic pain ≥ 0.3 when demographic parameters are entered&#xD;
             into a logistic regression model developed from a previous cohort. (Initial pain score&#xD;
             entered into this model will be based on the highest pain severity over the initial 24&#xD;
             hours of hospital admission).&#xD;
&#xD;
          -  European American or African American&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unwilling to take study drug&#xD;
&#xD;
          -  Allergy to fish oil or corn/soybean oil.&#xD;
&#xD;
          -  Patient taking clopidogrel (Plavix)&#xD;
&#xD;
          -  Patient taking warfarin or dabigatran.&#xD;
&#xD;
          -  Substantial comorbid injury (e.g. long bone fracture)&#xD;
&#xD;
          -  Pregnancy/Breastfeeding&#xD;
&#xD;
          -  Prisoner status&#xD;
&#xD;
          -  Chronic daily opioid use prior to burn (&gt;20 mg oral daily morphine equivalents).&#xD;
&#xD;
          -  Active psychosis, suicidal ideation, or homicidal ideation&#xD;
&#xD;
          -  Requires an escharotomy or fasciotomy for the treatment of burn injury.&#xD;
&#xD;
          -  Has a disorder of pain processing or diminished capacity to perceive pain (congenital&#xD;
             insensitivity to pain)&#xD;
&#xD;
          -  Known Child-Pugh liver disease severity classification B or C.&#xD;
&#xD;
          -  Known chronic kidney disease stage 4 or higher (GFR≤29).&#xD;
&#xD;
          -  Known Hemophilia A/B&#xD;
&#xD;
          -  Known bleeding dyscrasia&#xD;
&#xD;
          -  History of an inability to tolerate fish oil or corn/soybean oil.&#xD;
&#xD;
          -  Severe gastroesophageal reflux disease&#xD;
&#xD;
          -  No other history or condition that would, in the investigator's judgment, indicate&#xD;
             that the patient would very likely be non-compliant with the study or unsuitable for&#xD;
             the study (e.g. might interfere with the study, confound interpretation, or endanger&#xD;
             patient).&#xD;
&#xD;
          -  Intubated and sedated at time of enrollment.&#xD;
&#xD;
          -  Hypersensitivity to Vitamin D3, ergocalciferol, calcitriol, alfacalcidol, calcipotriol&#xD;
&#xD;
          -  Hypercalcemia (if not already completed, this will be assessed by clinical labs with&#xD;
             albumin correction prior to enrollment).&#xD;
&#xD;
          -  Hypervitaminosis&#xD;
&#xD;
          -  Sarcoidosis&#xD;
&#xD;
          -  Hyperphosphatemia&#xD;
&#xD;
          -  Arteriosclerosis&#xD;
&#xD;
          -  Active myocardial ischemia&#xD;
&#xD;
          -  Frequent antacid use (calcium carbonate, cimetidine)&#xD;
&#xD;
          -  Cholestyramine or Colestipol use&#xD;
&#xD;
          -  Taking Vitamin D supplements in excess of 800 IU daily.&#xD;
&#xD;
          -  Taking &gt;1g of fish oil per day.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthew C Mauck, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of North Carolina, Chapel Hill</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Of North Carolina</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27517</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>September 20, 2017</study_first_submitted>
  <study_first_submitted_qc>October 16, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 18, 2017</study_first_posted>
  <results_first_submitted>April 29, 2021</results_first_submitted>
  <results_first_submitted_qc>July 23, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">July 26, 2021</results_first_posted>
  <last_update_submitted>July 23, 2021</last_update_submitted>
  <last_update_submitted_qc>July 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>burn injury</keyword>
  <keyword>thermal burn injury</keyword>
  <keyword>omega 3 fatty acids</keyword>
  <keyword>vitamin D</keyword>
  <keyword>fish oil</keyword>
  <keyword>chronic pain</keyword>
  <keyword>chronic pain due to trauma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chronic Pain</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
    <mesh_term>Burns</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
    <mesh_term>Vitamins</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Deidentified individual data that supports the results will be shared on request provided the investigator who proposes to use the data has approval from an Institutional Review Board (IRB), Independent Ethics Committee (IEC), or Research Ethics Board (REB), as applicable, and executes a data use/sharing agreement with the University of North Carolina (UNC) independently.</ipd_description>
    <ipd_time_frame>12-36 months following publication</ipd_time_frame>
    <ipd_access_criteria>Deidentified individual data that supports the results will be shared provided the investigator who proposes to use the data has approval from an Institutional Review Board (IRB), Independent Ethics Committee (IEC), or Research Ethics Board (REB), as applicable, and executes a data use/sharing agreement with UNC independently.</ipd_access_criteria>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 28, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/76/NCT03313076/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>n-3 PUFA (O3FA) + Vitamin D3</title>
          <description>4g fish oil in 4 softgels (n-3 PUFA/O3FA) + 2000 IU Vitamin D3 in 1 capsule&#xD;
Omega-3 fatty acids (fish oil): 4 capsules. This will be administered daily, by mouth for 6 weeks&#xD;
Vitamin D3 (cholecalciferol): 1 capsule containing 2000 IU of Vitamin D3. This will be administered daily, by mouth for 6 weeks following enrollment.</description>
        </group>
        <group group_id="P2">
          <title>n-3 PUFA (O3FA) Placebo + Vitamin D3</title>
          <description>4g of corn/soy oil blend in 4 softgels + 2000 IU Vitamin D3 in 1 capsule&#xD;
Vitamin D3 (cholecalciferol): 1 capsule containing 2000 IU of Vitamin D3. This will be administered daily, by mouth for 6 weeks following enrollment.&#xD;
Omega-3 fatty acid placebo: 4g of corn/soy oil blend in 4 softgels. This will be administered daily, by mouth for 6 weeks following enrollment.</description>
        </group>
        <group group_id="P3">
          <title>n-3 PUFAs (O3FA) + Vitamin D3 Placebo</title>
          <description>4g fish oil in 4 softgels (n-3 PUFA/O3FA) + Vitamin D3 matching Placebo, an inert white powder placebo in 1 capsule&#xD;
Omega-3 fatty acids (fish oil): 4 capsules This will be administered daily, by mouth for 6 weeks&#xD;
Vitamin D3 (cholecalciferol) placebo: 1 capsule containing inert substance. This will be administered daily, by mouth for 6 weeks following enrollment.</description>
        </group>
        <group group_id="P4">
          <title>n-3 PUFA (O3FA) Placebo + Vitamin D3 Placebo</title>
          <description>4g n-3 PUFA/O3FA Matching Placebo, a corn/soy oil blend in 4 softgels + inert white powder Vitamin D3 matching placebo in 1 capsule&#xD;
Vitamin D3 (cholecalciferol) placebo: 1 capsule containing inert substance. This will be administered daily, by mouth for 6 weeks following enrollment.&#xD;
Omega-3 fatty acid placebo: 4g of corn/soy oil blend in 4 softgels. This will be administered daily, by mouth for 6 weeks following enrollment.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>n-3 PUFA (O3FA) + Vitamin D3</title>
          <description>4g fish oil in 4 softgels (n-3 PUFA/O3FA) + 2000 IU Vitamin D3 in 1 capsule&#xD;
Omega-3 fatty acids (fish oil): 4 capsules This will be administered daily, by mouth for 6 weeks&#xD;
Vitamin D3 (cholecalciferol): 1 capsule containing 2000 IU of Vitamin D3. This will be administered daily, by mouth for 6 weeks following enrollment.</description>
        </group>
        <group group_id="B2">
          <title>n-3 PUFA (O3FA) Placebo + Vitamin D3</title>
          <description>4g of corn/soy oil blend in 4 softgels + 2000 IU Vitamin D3 in 1 capsule&#xD;
Vitamin D3 (cholecalciferol): 1 capsule containing 2000 IU of Vitamin D3. This will be administered daily, by mouth for 6 weeks following enrollment.&#xD;
Omega-3 fatty acid placebo: 4g of corn/soy oil blend in 4 softgels. This will be administered daily, by mouth for 6 weeks following enrollment.</description>
        </group>
        <group group_id="B3">
          <title>n-3 PUFAs (O3FA) + Vitamin D3 Placebo</title>
          <description>4g fish oil in 4 softgels (n-3 PUFA/O3FA) + Vitamin D3 matching Placebo, an inert white powder placebo in 1 capsule&#xD;
Omega-3 fatty acids (fish oil): 4 capsules This will be administered daily, by mouth for 6 weeks&#xD;
Vitamin D3 (cholecalciferol) placebo: 1 capsule containing inert substance. This will be administered daily, by mouth for 6 weeks following enrollment.</description>
        </group>
        <group group_id="B4">
          <title>n-3 PUFA (O3FA) Placebo + Vitamin D3 Placebo</title>
          <description>4g n-3 PUFA/O3FA Matching Placebo, a corn/soy oil blend in 4 softgels + inert white powder Vitamin D3 matching placebo in 1 capsule&#xD;
Vitamin D3 (cholecalciferol) placebo: 1 capsule containing inert substance. This will be administered daily, by mouth for 6 weeks following enrollment.&#xD;
Omega-3 fatty acid placebo: 4g of corn/soy oil blend in 4 softgels. This will be administered daily, by mouth for 6 weeks following enrollment.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="5"/>
            <count group_id="B5" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38.8" spread="13.7"/>
                    <measurement group_id="B2" value="34.7" spread="12.6"/>
                    <measurement group_id="B3" value="26.9" spread="6.9"/>
                    <measurement group_id="B4" value="30.7" spread="9.39"/>
                    <measurement group_id="B5" value="32.6" spread="11.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Black American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Education</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Completed High School</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-high school education</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>College Graduate or beyond</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Income</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>&lt;$40,000/year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>$40,000-$59,999/year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>$60,000-$99,999/year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;$100,000/year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Refused/Don't know</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total Body Surface Area Burned</title>
          <description>Total body surface area affected by the burn</description>
          <units>Percent total body surface area burned</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.8" spread="4.01"/>
                    <measurement group_id="B2" value="7.9" spread="6.4"/>
                    <measurement group_id="B3" value="6.0" spread="4.7"/>
                    <measurement group_id="B4" value="5.3" spread="3.9"/>
                    <measurement group_id="B5" value="6.1" spread="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Type of Thermal Burn</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Flame</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Contact</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Scald</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Qualitative Review of Treatment-Related Adverse Events</title>
        <description>A primary objective of this pilot study is to ensure safety of both treatments as well as combined. A qualitative review of treatment-related adverse events will be performed and a determination about the degree of relatedness of each adverse event with the intervention using CTCAE criteria will be made as CTCAE criteria assesses relatedness to therapy. Investigator reviewing the details of each adverse event rated the likelihood of relatedness to the study drug on a scale: (unrelated, unlikely, possible, probably, definitely).</description>
        <time_frame>6 weeks following burn injury</time_frame>
        <population>Enrolled participants who initiated study treatment</population>
        <group_list>
          <group group_id="O1">
            <title>n-3 PUFA (O3FA) + Vitamin D3</title>
            <description>4g fish oil in 4 softgels (n-3 PUFA/O3FA) + 2000 IU Vitamin D3 in 1 capsule&#xD;
Omega-3 fatty acids (fish oil): 4 capsules.This will be administered daily, by mouth for 6 weeks&#xD;
Vitamin D3 (cholecalciferol): 1 capsule containing 2000 IU of Vitamin D3. This will be administered daily, by mouth for 6 weeks following enrollment.</description>
          </group>
          <group group_id="O2">
            <title>n-3 PUFAs (O3FA) + Vitamin D3 Placebo</title>
            <description>4g fish oil in 4 softgels (n-3 PUFA/O3FA) + Vitamin D3 matching Placebo, an inert white powder placebo in 1 capsule&#xD;
Omega-3 fatty acids (fish oil): 4 capsules. This will be administered daily, by mouth for 6 weeks&#xD;
Vitamin D3 (cholecalciferol) placebo: 1 capsule containing inert substance. This will be administered daily, by mouth for 6 weeks following enrollment.</description>
          </group>
          <group group_id="O3">
            <title>n-3 PUFA (O3FA) Placebo + Vitamin D3</title>
            <description>4g of corn/soy oil blend in 4 softgels + 2000 IU Vitamin D3 in 1 capsule&#xD;
Vitamin D3 (cholecalciferol): 1 capsule containing 2000 IU of Vitamin D3. This will be administered daily, by mouth for 6 weeks following enrollment.&#xD;
Omega-3 fatty acid placebo: 4g of corn/soy oil blend in 4 softgels. This will be administered daily, by mouth for 6 weeks following enrollment.</description>
          </group>
          <group group_id="O4">
            <title>n-3 PUFA (O3FA) Placebo + Vitamin D3 Placebo</title>
            <description>4g n-3 PUFA/O3FA Matching Placebo, a corn/soy oil blend in 4 softgels + inert white powder Vitamin D3 matching placebo in 1 capsule&#xD;
Vitamin D3 (cholecalciferol) placebo: 1 capsule containing inert substance. This will be administered daily, by mouth for 6 weeks following enrollment.&#xD;
Omega-3 fatty acid placebo: 4g of corn/soy oil blend in 4 softgels. This will be administered daily, by mouth for 6 weeks following enrollment.</description>
          </group>
        </group_list>
        <measure>
          <title>Qualitative Review of Treatment-Related Adverse Events</title>
          <description>A primary objective of this pilot study is to ensure safety of both treatments as well as combined. A qualitative review of treatment-related adverse events will be performed and a determination about the degree of relatedness of each adverse event with the intervention using CTCAE criteria will be made as CTCAE criteria assesses relatedness to therapy. Investigator reviewing the details of each adverse event rated the likelihood of relatedness to the study drug on a scale: (unrelated, unlikely, possible, probably, definitely).</description>
          <population>Enrolled participants who initiated study treatment</population>
          <units>adverse events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Unrelated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unlikely Related</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Possibly Related</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Probably Related</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Definitely Related</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percent of Participants Who Are Compliant With Follow-up (Feasibility)</title>
        <description>The primary objective of this pilot study is to ensure that the investigators are able to make follow-up assessments on a majority of participants. The percent of participants who are compliant with follow-up will be determined 6 weeks following major thermal burn injury. Feasibility is defined as &gt;80% of enrolled participants at 6 weeks following Major Thermal Burn Injury (MThBI).</description>
        <time_frame>6 weeks following burn injury</time_frame>
        <population>After informed consent, initial survey completion, and randomization, 2 participants in the n-3 PUFA (O3FA) + Vitamin D3 dropped out of the study and were not included in these analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>n-3 PUFA (O3FA) + Vitamin D3</title>
            <description>4g fish oil in 4 softgels (n-3 PUFA/O3FA) + 2000 IU Vitamin D3 in 1 capsule&#xD;
Omega-3 fatty acids (fish oil): 4 capsules.This will be administered daily, by mouth for 6 weeks&#xD;
Vitamin D3 (cholecalciferol): 1 capsule containing 2000 IU of Vitamin D3. This will be administered daily, by mouth for 6 weeks following enrollment.</description>
          </group>
          <group group_id="O2">
            <title>n-3 PUFA (O3FA) Placebo + Vitamin D3</title>
            <description>4g of corn/soy oil blend in 4 softgels + 2000 IU Vitamin D3 in 1 capsule&#xD;
Vitamin D3 (cholecalciferol): 1 capsule containing 2000 IU of Vitamin D3. This will be administered daily, by mouth for 6 weeks following enrollment.&#xD;
Omega-3 fatty acid placebo: 4g of corn/soy oil blend in 4 softgels. This will be administered daily, by mouth for 6 weeks following enrollment.</description>
          </group>
          <group group_id="O3">
            <title>n-3 PUFAs (O3FA) + Vitamin D3 Placebo</title>
            <description>4g fish oil in 4 softgels (n-3 PUFA/O3FA) + Vitamin D3 matching Placebo, an inert white powder placebo in 1 capsule&#xD;
Omega-3 fatty acids (fish oil): 4 capsules.This will be administered daily, by mouth for 6 weeks&#xD;
Vitamin D3 (cholecalciferol) placebo: 1 capsule containing inert substance. This will be administered daily, by mouth for 6 weeks following enrollment.</description>
          </group>
          <group group_id="O4">
            <title>n-3 PUFA (O3FA) Placebo + Vitamin D3 Placebo</title>
            <description>4g n-3 PUFA/O3FA Matching Placebo, a corn/soy oil blend in 4 softgels + inert white powder Vitamin D3 matching placebo in 1 capsule&#xD;
Vitamin D3 (cholecalciferol) placebo: 1 capsule containing inert substance. This will be administered daily, by mouth for 6 weeks following enrollment.&#xD;
Omega-3 fatty acid placebo: 4g of corn/soy oil blend in 4 softgels. This will be administered daily, by mouth for 6 weeks following enrollment.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Participants Who Are Compliant With Follow-up (Feasibility)</title>
          <description>The primary objective of this pilot study is to ensure that the investigators are able to make follow-up assessments on a majority of participants. The percent of participants who are compliant with follow-up will be determined 6 weeks following major thermal burn injury. Feasibility is defined as &gt;80% of enrolled participants at 6 weeks following Major Thermal Burn Injury (MThBI).</description>
          <population>After informed consent, initial survey completion, and randomization, 2 participants in the n-3 PUFA (O3FA) + Vitamin D3 dropped out of the study and were not included in these analyses.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="50"/>
                    <measurement group_id="O3" value="83.3"/>
                    <measurement group_id="O4" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>By Group Efficacy Estimates Over Year Following Thermal Burn Injury</title>
        <description>Estimates of efficacy will be obtained via repeated measures analysis of pain severity over the 1 year following injury using mixed effects models. Pain will be assessed using a 0-10 numeric rating scale with 0 indicating no pain and 10 indicating pain as severe as you can imagine. Higher scores represent worse outcome. These values (collected in identical fashion over 1 year following burn injury) will be entered into a linear mixed model, and overall effect estimates (beta coefficients) among groups will be determined. Final model was a piece-wise linear mixed model, with a cut-point at 6 weeks. Mixed models were adjusted for age, sex, race, initial pain severity. Every 1 unit change in beta coefficient represents a 1 unit change in pain severity on the 0-10 numeric rating scale.</description>
        <time_frame>Over 1 year following MThBI</time_frame>
        <population>Given the 2x2 factorial design, comparisons were made to assess the differences between one treatment and placebo regardless of the other treatment. E.g. groups were combined to assess whether there was any difference between Vitamin D and placebo regardless of O3FA treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Omega-3</title>
            <description>Omega 3 active treatment</description>
          </group>
          <group group_id="O2">
            <title>No Omega 3 Treatment</title>
            <description>Omega 3 placebo</description>
          </group>
          <group group_id="O3">
            <title>Vitamin D</title>
            <description>Vitamin D active treatment</description>
          </group>
          <group group_id="O4">
            <title>No Vitamin D Treatment</title>
            <description>Vitamin D placebo</description>
          </group>
        </group_list>
        <measure>
          <title>By Group Efficacy Estimates Over Year Following Thermal Burn Injury</title>
          <description>Estimates of efficacy will be obtained via repeated measures analysis of pain severity over the 1 year following injury using mixed effects models. Pain will be assessed using a 0-10 numeric rating scale with 0 indicating no pain and 10 indicating pain as severe as you can imagine. Higher scores represent worse outcome. These values (collected in identical fashion over 1 year following burn injury) will be entered into a linear mixed model, and overall effect estimates (beta coefficients) among groups will be determined. Final model was a piece-wise linear mixed model, with a cut-point at 6 weeks. Mixed models were adjusted for age, sex, race, initial pain severity. Every 1 unit change in beta coefficient represents a 1 unit change in pain severity on the 0-10 numeric rating scale.</description>
          <population>Given the 2x2 factorial design, comparisons were made to assess the differences between one treatment and placebo regardless of the other treatment. E.g. groups were combined to assess whether there was any difference between Vitamin D and placebo regardless of O3FA treatment.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Day 1)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="13"/>
                    <count group_id="O4" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.19" spread="1.15"/>
                    <measurement group_id="O2" value="7.57" spread="1.83"/>
                    <measurement group_id="O3" value="7.01" spread="1.72"/>
                    <measurement group_id="O4" value="7.65" spread="1.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.7" spread="2.21"/>
                    <measurement group_id="O2" value="5.50" spread="2.21"/>
                    <measurement group_id="O3" value="5" spread="2.65"/>
                    <measurement group_id="O4" value="6.09" spread="2.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5" spread="2.99"/>
                    <measurement group_id="O2" value="3.8" spread="3.01"/>
                    <measurement group_id="O3" value="3.22" spread="2.33"/>
                    <measurement group_id="O4" value="4.91" spread="3.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" spread="2.45"/>
                    <measurement group_id="O2" value="2.8" spread="2.49"/>
                    <measurement group_id="O3" value="1.9" spread="1.97"/>
                    <measurement group_id="O4" value="2.90" spread="2.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.73" spread="2.20"/>
                    <measurement group_id="O2" value="2.33" spread="1.94"/>
                    <measurement group_id="O3" value="1.6" spread="1.78"/>
                    <measurement group_id="O4" value="2.4" spread="2.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.22" spread="1.48"/>
                    <measurement group_id="O2" value="1.43" spread="1.27"/>
                    <measurement group_id="O3" value="1" spread="1.15"/>
                    <measurement group_id="O4" value="1.56" spread="1.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" spread="1.58"/>
                    <measurement group_id="O2" value="1.57" spread="2.94"/>
                    <measurement group_id="O3" value="0.75" spread="1.04"/>
                    <measurement group_id="O4" value="2.33" spread="2.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.67" spread="1.15"/>
                    <measurement group_id="O2" value="0.33" spread="0.58"/>
                    <measurement group_id="O3" value="0.25" spread="0.5"/>
                    <measurement group_id="O4" value="1.0" spread="1.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.14" spread="1.46"/>
                    <measurement group_id="O2" value="0.33" spread="0.82"/>
                    <measurement group_id="O3" value="0.67" spread="1.03"/>
                    <measurement group_id="O4" value="0.86" spread="1.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="2.17"/>
                    <measurement group_id="O2" value="0.5" spread="1.0"/>
                    <measurement group_id="O3" value="0.6" spread="0.89"/>
                    <measurement group_id="O4" value="1.25" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.276</p_value>
            <p_value_desc>The final, adjusted p-value threshold of 0.0492, using the O'Brien-Fleming approach, allows for a statistical &quot;penalty&quot; to be assessed because of the interim analysis.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>The model was adjusted for age, sex, race, treatment interaction, initial pain severity, and total body surface area burned.</method_desc>
            <param_type>Slope</param_type>
            <param_value>-0.84</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.32</ci_lower_limit>
            <ci_upper_limit>0.63</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.336</p_value>
            <p_value_desc>The final, adjusted p-value threshold of 0.0492, using the O'Brien-Fleming approach, allows for a statistical &quot;penalty&quot; to be assessed because of the interim analysis.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>The model was adjusted for age, sex, race, treatment interaction, initial pain severity, and total body surface area burned.</method_desc>
            <param_type>Slope</param_type>
            <param_value>0.72</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.71</ci_lower_limit>
            <ci_upper_limit>2.14</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Sensitivity analysis adjusting for an influential observation (using the dfbeta approach) that could produce spurious results from a small trial dataset</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.004</p_value>
            <p_value_desc>The final, adjusted p-value threshold of 0.0492, using the O'Brien-Fleming approach, allows for a statistical &quot;penalty&quot; to be assessed because of the interim analysis.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>The model was adjusted for age, sex, race, treatment interaction, initial pain severity, and total body surface area burned.</method_desc>
            <param_type>Slope</param_type>
            <param_value>-2.33</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.76</ci_lower_limit>
            <ci_upper_limit>-0.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Sensitivity analysis adjusting for an influential observation (using the dfbeta approach) that could produce spurious results from a small trial dataset</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.139</p_value>
            <p_value_desc>The final, adjusted p-value threshold of 0.0492, using the O'Brien-Fleming approach, allows for a statistical &quot;penalty&quot; to be assessed because of the interim analysis.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <method_desc>The model was adjusted for age, sex, race, treatment interaction, initial pain severity, and total body surface area burned.</method_desc>
            <param_type>Slope</param_type>
            <param_value>0.92</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.25</ci_lower_limit>
            <ci_upper_limit>2.09</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sex Differences in Treatment Response Based on Pain Scores</title>
        <description>Examines existence of gender-based treatment response differences in pain severity measured by a 0-10 numeric rating scale where 0 is no pain and 10 is the most severe pain. Higher scores reflect greater pain (poor outcome).</description>
        <time_frame>6 weeks following burn injury</time_frame>
        <population>The population included were participants who responded to the graft site pain severity question at the 6-week follow-up surveys. Treatment assignment of Omega-3 fatty acids or no Omega-3 fatty acids was considered independent of Vitamin D treatment. Treatment assignment of Vitamin D or no Vitamin D treatment was considered independent of Omega-3 fatty acid treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Omega-3</title>
            <description>Omega 3 active treatment</description>
          </group>
          <group group_id="O2">
            <title>No Omega 3 Treatment</title>
            <description>Omega 3 placebo</description>
          </group>
          <group group_id="O3">
            <title>Vitamin D</title>
            <description>Vitamin D active treatment</description>
          </group>
          <group group_id="O4">
            <title>No Vitamin D Treatment</title>
            <description>Vitamin D placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Sex Differences in Treatment Response Based on Pain Scores</title>
          <description>Examines existence of gender-based treatment response differences in pain severity measured by a 0-10 numeric rating scale where 0 is no pain and 10 is the most severe pain. Higher scores reflect greater pain (poor outcome).</description>
          <population>The population included were participants who responded to the graft site pain severity question at the 6-week follow-up surveys. Treatment assignment of Omega-3 fatty acids or no Omega-3 fatty acids was considered independent of Vitamin D treatment. Treatment assignment of Vitamin D or no Vitamin D treatment was considered independent of Omega-3 fatty acid treatment.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Male</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.43" spread="1.81"/>
                    <measurement group_id="O2" value="1.80" spread="3.49"/>
                    <measurement group_id="O3" value="0.33" spread="0.81"/>
                    <measurement group_id="O4" value="2.83" spread="3.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Female</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.00" spread="1.00"/>
                    <measurement group_id="O2" value="1.00" spread="1.42"/>
                    <measurement group_id="O3" value="2" spread="0"/>
                    <measurement group_id="O4" value="1.33" spread="1.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>General Mental Health as Measured by the Short Form (SF)-12 General Mental Health Component Scores</title>
        <description>Assessment of mental health will be determined by the short form (SF)-12 mental component score. The short form SF-12 Health Survey is a 12-item participant completed questionnaire to measure general health. It includes a mental component score (MCS): ranging from 0 to 100 points. Low values represent a poor health state and high values represent a good mental health.</description>
        <time_frame>6 weeks following burn injury</time_frame>
        <population>The population included were participants who responded to the graft site pain severity question at the 6-week follow-up surveys. Treatment assignment of Omega-3 fatty acids or no Omega-3 fatty acids was considered independent of Vitamin D treatment. Treatment assignment of Vitamin D or no Vitamin D treatment was considered independent of Omega-3 fatty acid treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Omega-3</title>
            <description>Omega 3 active treatment</description>
          </group>
          <group group_id="O2">
            <title>No Omega 3 Treatment</title>
            <description>Omega 3 placebo</description>
          </group>
          <group group_id="O3">
            <title>Vitamin D</title>
            <description>Vitamin D active treatment</description>
          </group>
          <group group_id="O4">
            <title>No Vitamin D Treatment</title>
            <description>Vitamin D placebo</description>
          </group>
        </group_list>
        <measure>
          <title>General Mental Health as Measured by the Short Form (SF)-12 General Mental Health Component Scores</title>
          <description>Assessment of mental health will be determined by the short form (SF)-12 mental component score. The short form SF-12 Health Survey is a 12-item participant completed questionnaire to measure general health. It includes a mental component score (MCS): ranging from 0 to 100 points. Low values represent a poor health state and high values represent a good mental health.</description>
          <population>The population included were participants who responded to the graft site pain severity question at the 6-week follow-up surveys. Treatment assignment of Omega-3 fatty acids or no Omega-3 fatty acids was considered independent of Vitamin D treatment. Treatment assignment of Vitamin D or no Vitamin D treatment was considered independent of Omega-3 fatty acid treatment.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.98" spread="9.98"/>
                    <measurement group_id="O2" value="48.29" spread="10.79"/>
                    <measurement group_id="O3" value="52.80" spread="6.37"/>
                    <measurement group_id="O4" value="46.16" spread="11.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>General Physical Health by Treatment Group Measured by the SF-12 General Physical Health Component Scores</title>
        <description>Assessment of physical health will be determined by the SF-12 physical component score. The SF-12 Health Survey is a 12 item participant completed questionnaire to measure general health. It includes a physical component score (PCS): ranging from 0 to 100 points. Low values represent a poor physical health and high values represent a good physical health.</description>
        <time_frame>6 weeks following burn injury</time_frame>
        <population>The population included were participants who responded to the graft site pain severity question at the 6-week follow-up surveys. Treatment assignment of Omega-3 fatty acids or no Omega-3 fatty acids was considered independent of Vitamin D treatment. Treatment assignment of Vitamin D or no Vitamin D treatment was considered independent of Omega-3 fatty acid treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Omega-3</title>
            <description>Omega 3 active treatment</description>
          </group>
          <group group_id="O2">
            <title>No Omega 3 Treatment</title>
            <description>Omega 3 placebo</description>
          </group>
          <group group_id="O3">
            <title>Vitamin D</title>
            <description>Vitamin D active treatment</description>
          </group>
          <group group_id="O4">
            <title>No Vitamin D Treatment</title>
            <description>Vitamin D placebo</description>
          </group>
        </group_list>
        <measure>
          <title>General Physical Health by Treatment Group Measured by the SF-12 General Physical Health Component Scores</title>
          <description>Assessment of physical health will be determined by the SF-12 physical component score. The SF-12 Health Survey is a 12 item participant completed questionnaire to measure general health. It includes a physical component score (PCS): ranging from 0 to 100 points. Low values represent a poor physical health and high values represent a good physical health.</description>
          <population>The population included were participants who responded to the graft site pain severity question at the 6-week follow-up surveys. Treatment assignment of Omega-3 fatty acids or no Omega-3 fatty acids was considered independent of Vitamin D treatment. Treatment assignment of Vitamin D or no Vitamin D treatment was considered independent of Omega-3 fatty acid treatment.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.84" spread="6.25"/>
                    <measurement group_id="O2" value="40.12" spread="6.40"/>
                    <measurement group_id="O3" value="40.83" spread="3.85"/>
                    <measurement group_id="O4" value="40.29" spread="7.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain Interference by Treatment Group Measured by the Brief Pain Inventory</title>
        <description>The degree to which pain interferes with important life function will be determined by the Brief Pain Inventory. This is a validated, self-reported scale that measures the severity of pain based on the average pain experienced and assesses impact of pain across 7 domains of life function (e.g., enjoyment of life, relationships, normal work). The total severity scores range from 0 (no interference) to 70 (maximum interference). Higher scores reflect greater pain interference.</description>
        <time_frame>6 weeks following burn injury</time_frame>
        <population>The population included were participants who responded to the graft site pain severity question at the 6-week follow-up surveys. Treatment assignment of Omega-3 fatty acids or no Omega-3 fatty acids was considered independent of Vitamin D treatment. Treatment assignment of Vitamin D or no Vitamin D treatment was considered independent of Omega-3 fatty acid treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Omega-3</title>
            <description>Omega 3 active treatment</description>
          </group>
          <group group_id="O2">
            <title>No Omega 3 Treatment</title>
            <description>Omega 3 placebo</description>
          </group>
          <group group_id="O3">
            <title>Vitamin D</title>
            <description>Vitamin D active treatment</description>
          </group>
          <group group_id="O4">
            <title>No Vitamin D Treatment</title>
            <description>Vitamin D placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Interference by Treatment Group Measured by the Brief Pain Inventory</title>
          <description>The degree to which pain interferes with important life function will be determined by the Brief Pain Inventory. This is a validated, self-reported scale that measures the severity of pain based on the average pain experienced and assesses impact of pain across 7 domains of life function (e.g., enjoyment of life, relationships, normal work). The total severity scores range from 0 (no interference) to 70 (maximum interference). Higher scores reflect greater pain interference.</description>
          <population>The population included were participants who responded to the graft site pain severity question at the 6-week follow-up surveys. Treatment assignment of Omega-3 fatty acids or no Omega-3 fatty acids was considered independent of Vitamin D treatment. Treatment assignment of Vitamin D or no Vitamin D treatment was considered independent of Omega-3 fatty acid treatment.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.60" spread="12.76"/>
                    <measurement group_id="O2" value="13.71" spread="20.30"/>
                    <measurement group_id="O3" value="5.5" spread="6.85"/>
                    <measurement group_id="O4" value="18.67" spread="19.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>After randomization through 6 weeks of active treatment</time_frame>
      <desc>Participants responded via weekly surveys to assess adverse events</desc>
      <group_list>
        <group group_id="E1">
          <title>n-3 PUFA (O3FA) + Vitamin D3</title>
          <description>4g fish oil in 4 softgels (n-3 PUFA/O3FA) + 2000 IU Vitamin D3 in 1 capsule&#xD;
Omega-3 fatty acids (fish oil): 4 capsules. This will be administered daily, by mouth for 6 weeks&#xD;
Vitamin D3 (cholecalciferol): 1 capsule containing 2000 IU of Vitamin D3. This will be administered daily, by mouth for 6 weeks following enrollment.</description>
        </group>
        <group group_id="E2">
          <title>n-3 PUFA (O3FA) Placebo + Vitamin D3</title>
          <description>4g of corn/soy oil blend in 4 softgels + 2000 IU Vitamin D3 in 1 capsule&#xD;
Vitamin D3 (cholecalciferol): 1 capsule containing 2000 IU of Vitamin D3. This will be administered daily, by mouth for 6 weeks following enrollment.&#xD;
Omega-3 fatty acid placebo: 4g of corn/soy oil blend in 4 softgels. This will be administered daily, by mouth for 6 weeks following enrollment.</description>
        </group>
        <group group_id="E3">
          <title>n-3 PUFAs (O3FA) + Vitamin D3 Placebo</title>
          <description>4g fish oil in 4 softgels (n-3 PUFA/O3FA) + Vitamin D3 matching Placebo, an inert white powder placebo in 1 capsule&#xD;
Omega-3 fatty acids (fish oil): 4 capsules. This will be administered daily, by mouth for 6 weeks&#xD;
Vitamin D3 (cholecalciferol) placebo: 1 capsule containing inert substance. This will be administered daily, by mouth for 6 weeks following enrollment.</description>
        </group>
        <group group_id="E4">
          <title>n-3 PUFA (O3FA) Placebo + Vitamin D3 Placebo</title>
          <description>4g n-3 PUFA/O3FA Matching Placebo, a corn/soy oil blend in 4 softgels + inert white powder Vitamin D3 matching placebo in 1 capsule&#xD;
Vitamin D3 (cholecalciferol) placebo: 1 capsule containing inert substance. This will be administered daily, by mouth for 6 weeks following enrollment.&#xD;
Omega-3 fatty acid placebo: 4g of corn/soy oil blend in 4 softgels. This will be administered daily, by mouth for 6 weeks following enrollment.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <description>Mild reduction in hemoglobin concentration</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Elevated PTT</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Gastrointestinal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Medication administration error</sub_title>
                <description>Medication administration/dosing error</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Mood Swings</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary Frequency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oral Sore</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Transient Hypoxemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dry Skin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Early termination because of pandemic delays</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Matt Mauck, MD, PhD</name_or_title>
      <organization>University of North Carolina at Chapel Hill</organization>
      <phone>919-966-5136</phone>
      <email>matt_mauck@med.unc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

